- Finland joins Denmark and Sweden to pause giving Moderna Inc's MRNA COVID-19 shots to men under the age of 30 due to the risk of heart inflammation.
- Related: Sweden, Denmark Pause Use Of Moderna COVID-19 Shot In Younger Individuals: What You Need To Know.
- Mika Salminen, director of the Finnish health institute, said Finland would instead give Pfizer Inc's PFE / BioNTech SE BNTX vaccine to men born in 1991 and later. Finland offers shots to people aged 12 and over.
- If a person has had the first shot with Moderna, Salminen said the second one could be Pfizer.
- The Norwegian Institute of Public Health also recommended that men under 30 consider the Pfizer jab, citing new data from Ontario, Canada, Norway, Sweden, and other countries.
- "A Nordic study involving Finland, Sweden, Norway, and Denmark found that men under the age of 30 who received Moderna Spikevax had a slightly higher risk than others of developing myocarditis," he said.
- The Finnish institute said the Nordic study would be published within a couple of weeks, and preliminary data had been sent to the European Medicines Agency for further assessment.
- Price Action: MRNA stock is up 3.60% at $313.20 during the market session on the last check Thursday.
- Image by Spencer Davis from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in